| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于表达免疫检查点调节因子的溶瘤病毒 | CN201580050076.8 | 2015-07-16 | CN107208069A | 2017-09-26 | N·西尔韦斯特雷; M·盖斯特; K·里特纳; J-B·马尔尚; C·蒂欧德勒特 |
| 本发明提供溶瘤病毒，其包含编码一或多种免疫检查点调节因子的核苷酸序列。还涉及药物组合物，其包含有效量的所述溶瘤病毒和，最终地，药学可接受的载体，以及涉及其用于治疗增生性疾病例如癌症的用途。 | ||||||
| 2 | Poxviral oncolytic vectors | US14249713 | 2014-04-10 | US09687515B2 | 2017-06-27 | Philippe Erbs; Johann Foloppe |
| The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | ||||||
| 3 | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス | JP2017502212 | 2015-07-16 | JP2017522025A | 2017-08-10 | ナタリー、シルベストル; ミシェル、ジェイスト; カローラ、リットナー; ジャン−バティスト、マルシャン; クリスティーヌ、チウデレ |
| 本発明は、1つ以上の免疫チェックポイントモジュレーターをコードするヌクレオチド配列を含んでなる腫瘍溶解性ウイルスを提供する。また、本発明は、当該腫瘍溶解性ウイルスの有効量および、最終的には薬学的に許容可能な賦形剤を含んでなる医薬組成物、ならびに癌等の増殖性疾患の治療のためのその使用にも関連する。 | ||||||
| 4 | GENES SUICIDE ET ASSOCIATIONS D'ANALOGUES DE NUCLEOBASES ET NUCLEOSIDES PYRIMIDIQUES AVEC DES GENES SUICIDE EN VUE D'UNE THERAPIE GENIQUE | EP95940324.0 | 1995-11-16 | EP0792369A1 | 1997-09-03 | TIRABY, Gérard; REYNES, Jean-Paul; TIRABY, Michèle; CAZAUX, Christophe; DROCOURT, Daniel |
| Two groups of hybrid suicide genes are disclosed, where the genes of one group specifically activate 5-fluorocytosine, a pyrimidine nucleobase analogue, while the genes of the other group activate azidothymidine, a pyrimidine nucleobase analogue, into derivatives toxic for mammalian cells. A variety of methods are also disclosed for selectively killing transfected tumour cells or immune cells using a single hybrid suicide gene or a combination of two hybrid suicide genes selected for the complementarity of their antimetabolic activities. Furthermore, eukaryotic vectors including two suicide gene expression units, i.e. a first unit sensitising the tumour cells to 5-fluorocytosine or 5-fluorouracil, and a second making HIV-infected cells synergistically resistant to azidothymidine. | ||||||
| 5 | BIOSYNTHETIC LABELING AND SEPARATION OF RNA | US15557391 | 2016-03-18 | US20180080061A1 | 2018-03-22 | Michael Cleary; Naoki Hida |
| Methods are provided for differential biosynthetic labeling of RNA, including identification of cell type-specific programs of gene expression. The methods and compositions of the invention allow detection and/or purification of RNAs with precise spatial and temporal resolution. In various embodiments of the invention, the methods are applied to animal cells, including cell lines, stem cells, selected lineages of organisms, and the like. | ||||||
| 6 | MICROVESICLE-MEDIATED DELIVERY OF THERAPEUTIC MOLECULES | US14384056 | 2013-03-13 | US20150079631A1 | 2015-03-19 | Xandra O. Breakefield; Mehmet Fatih Bolukbasi; Arda Mizrak; Okay Saydam |
| Disclosed herein are methods to produce extracellular vesicles such as microvesicles that contain therapeutic molecules. Such therapeutic molecules can be nucleic acid or protein or combinations thereof. Methods to deliver the therapeutic molecules to a cell are also disclosed. Therapeutic methods of treatment of disease such as cancer by delivering conditionally a lethal molecule to the cancer cells by administering microvesicles are also disclosed. | ||||||
| 7 | POXVIRAL ONCOLYTIC VECTORS | US14249713 | 2014-04-10 | US20150017126A1 | 2015-01-15 | Philippe ERBS; Johann Foloppe |
| The present invention relates to a poxvirus comprising a defective F4L and/or I4L gene, to composition comprising such poxvirus and to the methods and use of such compositions and poxviruses for therapeutic purposes, and more particularly for the treatment of cancer. | ||||||
| 8 | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases | US343923 | 1994-11-17 | US5856153A | 1999-01-05 | Gerard Tiraby; Jean-Paul Reynes; Michele Tiraby; Christophe Cazaux; Daniel Drocourt |
| The present invention relates to two groups of suicide hybrid genes in which genes from one group specifically activate the pyrimidine nucleobase analog 5-fluorocytosine and genes from the other group activate the pyrimidine nucleoside analog azidothymidine to derivatives toxic for mammalian cells.The present invention further relates to methods for the selective killing of transfected tumor cells or immune cells using a single suicide hybrid gene or the combination of two suicide hybrid genes selected for a complementarity in their antimetabolic action. The present invention also relates to eukaryotic vectors comprising two expression suicide gene units, the first permitting the sensitization of tumor cells to 5-fluorocytosine and the second permitting the sensitization of HIV-infected cells to Azidothymidine in a synergistic fashion. | ||||||
| 9 | SYNTHETIC FLUOROURIDINE-ACTIVATING ENZYME FOR CANCER THERAPY | EP05743019.1 | 2005-05-10 | EP1747270A2 | 2007-01-31 | DEGANO, Massimo; c/o DIBIT San Raffaele; GIABBAI, Barbara; c/o DIBIT San Raffaele |
| A chimeric protein essentially comprising a first moiety having an activity of nucleoside hydrolase (NH) and a second moiety having an activity of uracil phosphorybosil transferase (UPRT), the first and the second moiety being optionally linked by an extra amino acid sequence, nucleic acids encoding for the same, vectors for use in suicide gene therapy, chemotherapeutic composition comprising the protein. | ||||||
| 10 | GENES SUICIDE ET ASSOCIATIONS D'ANALOGUES DE NUCLEOBASES ET NUCLEOSIDES PYRIMIDIQUES AVEC DES GENES SUICIDE EN VUE D'UNE THERAPIE GENIQUE | EP95940324.7 | 1995-11-16 | EP0792369B1 | 2000-04-05 | TIRABY, Gérard; REYNES, Jean-Paul; TIRABY, Michèle; CAZAUX, Christophe; DROCOURT, Daniel |
| Two groups of hybrid suicide genes are disclosed, where the genes of one group specifically activate 5-fluorocytosine, a pyrimidine nucleobase analogue, while the genes of the other group activate azidothymidine, a pyrimidine nucleobase analogue, into derivatives toxic for mammalian cells. A variety of methods are also disclosed for selectively killing transfected tumour cells or immune cells using a single hybrid suicide gene or a combination of two hybrid suicide genes selected for the complementarity of their antimetabolic activities. Furthermore, eukaryotic vectors including two suicide gene expression units, i.e. a first unit sensitising the tumour cells to 5-fluorocytosine or 5-fluorouracil, and a second making HIV-infected cells synergistically resistant to azidothymidine. | ||||||
| 11 | ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS | EP15738359.7 | 2015-07-16 | EP3169341A1 | 2017-05-24 | SILVESTRE, Nathalie; GEIST, Michel; RITTNER, Karola; MARCHAND, Jean-Baptiste; THIOUDELLET, Christine |
| The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers. | ||||||
| 12 | BIOSYNTHETIC LABELING AND SEPARATION OF RNA | PCT/US2016023232 | 2016-03-18 | WO2016154040A3 | 2016-11-17 | CLEARY MICHAEL; HIDA NAOKI |
| Methods are provided for differential biosynthetic labeling of RNA, including identification of cell type-specific programs of gene expression. The methods and compositions of the invention allow detection and/or purification of RNAs with precise spatial and temporal resolution. In various embodiments of the invention, the methods are applied to animal cells, including cell lines, stem cells, selected lineages of organisms, and the like. | ||||||
| 13 | SYNTHETIC FLUOROURIDINE-ACTIVATING ENZYME FOR CANCER THERAPY | PCT/IT2005000271 | 2005-05-10 | WO2005108562A3 | 2006-01-26 | DEGANO MASSIMO; GIABBAI BARBARA |
| A chimeric protein essentially comprising a first moiety having an activity of nucleoside hydrolase (NH) and a second moiety having an activity of uracil phosphorybosil transferase (UPRT), the first and the second moiety being optionally linked by an extra amino acid sequence, nucleic acids encoding for the same, vectors for use in suicide gene therapy, chemotherapeutic composition comprising the protein. | ||||||
QQ群二维码
意见反馈
意见反馈